The Acute Effect of Chlorpromazine on Body Temperature in Intensive Care Unit Patients
Öz
Aim: Hypothermia is a rare complication of antipsychotic drugs but serious outcomes including death may result. In this study, we aimed to investigate body temperature alterations in acute phase of chlorpromazine treatment, the relationship of inflammatory indicators and risk factors for hypothermic effect in intensive care unit (ICU) patients.
Materials and methods: 63 intensive care patients who needed sedative treatment due to agitation were divided into two groups as Group 1 (n = 30) with temperatures ≤ 38°C, and Group 2 (n = 33) with temperatures > 38°C according to baseline body temperatures. Also, recurrent measurements for 12 hours were made at specific intervals following 25 mg intravenous chlorpromazine.
Results: In Group 1, decrease in body temperatures was significant from 4th to 12th hours (p < 0.01), while in Group 2, significant decreases in body temperatures at all measurement hours were observed (p < 0.01). Temperature changes (delta temperature) observed at specific measurement intervals were significantly higher in Group 2 compared to Group 1. That difference was statistically significant at all intervals except for ΔTemperature B-6 (p < 0.05). The odds of hypothermic effects by chlorpromazine were 16%, 46%, 3%, and 18% for Acute Physiology and Chronic Health Evaluation II, procalcitonin, C-reactive protein, and white blood cells, respectively.
Conclusion: Chlorpromazine treatment applied for agitation in ICU patients was associated with acute hypothermic effect. Severity of disease and comorbidities might increase risk of hypothermia, and inflammatory biomarkers might be predictors of adverse drug reaction.
Anahtar Kelimeler
adverse drug reaction, body temperature changes, chlorpromazine, intensive care unit, psychomotor agitation
Destekleyen Kurum
Yok
Proje Numarası
Yok
Teşekkür
The authors would like to thank Prof. Dr. Jale Bengi Çelik and Prof. Dr. Ateş Duman for their contribution to the editing of the article.
Kaynakça
- 1. Boschi G, Launay N, Rips R. Neuroleptic-induced hypothermia in mice: lack of evidence for a central mechanism. J Pharmac. 1987;90:745–51.
- 2. Ginawi OT. Possible involvement of opioid receptors in moclobemide-induced hypothermia in mice. Pharmacol Res. 2003;48:237–40.
- 3. Asanami S, Shimono K. Species-level differences between mice and rats in regards to micronucleus induction with the hypothermia-inducing drug haloperidol. Mutat Res. 2009;676:102-5.
- 4. Van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol. 2007;63:627-631.
- 5. Gocke E. Review of the genotoxic properties of chlorpromazine and related phenothiazines. Mutat Res. 1996;366:9-21.
- 6. Lopez-Munoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17:113-135.
- 7. Adams F. Neuropsychiatric evaluation and treatment of delirium in the critically ill cancer patient. Cancer Bulletin. 1984;36:156-160.
- 8. Coppolo DP, May JJ. Self-extubations: A 12 month experience. Chest. 1990;98:165-169.
- 9. Robinson BR, Mueller EW, Henson K, et al. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. J Trauma. 2008;65:517-26.
- 10. Adams F. Emergency intravenous sedation of the delirious medically ill patient. J Clin Psychiatry. 1988;49:22-26.